- Home
- ADPT vs XENE Comparison
ADPT vs XENE Comparison
Compare ADPT & XENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- XENE
- Stock Information
- Founded
- ADPT 2009
- XENE 1996
- Country
- ADPT United States
- XENE Canada
- Employees
- ADPT N/A
- XENE N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- XENE Biotechnology: Pharmaceutical Preparations
- Sector
- ADPT Health Care
- XENE Health Care
- Exchange
- ADPT Nasdaq
- XENE Nasdaq
- Market Cap
- ADPT 2.6B
- XENE 2.9B
- IPO Year
- ADPT 2019
- XENE 2014
- Fundamental
- Price
- ADPT $16.88
- XENE $39.18
- Analyst Decision
- ADPT Strong Buy
- XENE Strong Buy
- Analyst Count
- ADPT 10
- XENE 10
- Target Price
- ADPT $15.10
- XENE $52.90
- AVG Volume (30 Days)
- ADPT 1.5M
- XENE 795.3K
- Earning Date
- ADPT 11-05-2025
- XENE 11-03-2025
- Dividend Yield
- ADPT N/A
- XENE N/A
- EPS Growth
- ADPT N/A
- XENE N/A
- EPS
- ADPT N/A
- XENE N/A
- Revenue
- ADPT $205,216,000.00
- XENE $7,500,000.00
- Revenue This Year
- ADPT $34.41
- XENE N/A
- Revenue Next Year
- ADPT $14.03
- XENE $207.88
- P/E Ratio
- ADPT N/A
- XENE N/A
- Revenue Growth
- ADPT 21.60
- XENE N/A
- 52 Week Low
- ADPT $4.27
- XENE $26.74
- 52 Week High
- ADPT $17.89
- XENE $46.00
- Technical
- Relative Strength Index (RSI)
- ADPT 59.44
- XENE 43.75
- Support Level
- ADPT $16.59
- XENE $40.79
- Resistance Level
- ADPT $17.76
- XENE $42.96
- Average True Range (ATR)
- ADPT 0.77
- XENE 1.59
- MACD
- ADPT -0.09
- XENE -0.33
- Stochastic Oscillator
- ADPT 50.12
- XENE 28.84
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.